Navigation Links
CNIO team presents a new strategy to personalise cancer therapies
Date:4/29/2014

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours. This complexity, which researchers were not aware of just a few years ago, calls for new tools to filter relevant genetic information for the implementation and development of personalised therapies targeted at specific characteristics within each individual tumour.

Researchers led by Manuel Hidalgo, Vice-Director of Translational Research at CNIO, have developed a new strategy to personalised medicine in advanced cancer patients with a poor prognosis. The study has been published in the journal Clinical Cancer Research. Applying this new tool, the treatments induced clinical responses in up to 77% of patients, either through the stabilisation of their condition or through a partial clinical response.

During the first phase, the authors analysed the genetic signature of the tumours specifically, the hundreds of millions of letters that make up the exome; the part of the genome whose information produces proteins in 23 patients suffering from advanced cancers, such as pancreatic adenocarcinomas and colon cancer. By using whole exome sequencing and bioinformatics analyses, researchers picked out mutations that could play an important role in the growth and spread of tumours.

The second part of the study involved the use of Avatar mice to study potentially effective treatments according to the patient's genetic signature. As Elena Garralda, predoctoral researcher from Hidalgo's Group, points out, avatar mice are "one of the key aspects of our research."

AVATAR MICE: A TESTING GROUND FOR DRUGS

Avatar mice are used as a testing ground, with each patient having their own equivalent animal, in order to study the effectiveness of drugs under real conditions: if the drug works in the avatar, the likelihood of it also working in the patient is very high.

Therefore, the treatments that worked best in the avatar mice were the ones given to patients. The results showed clinical benefit, either the stabilisation of the disease or a partial clinical response, in up to 77% of patients.

"We have demonstrated that it is possible to apply our personalised cancer treatment strategy to the clinic", says Garralda, adding: "as we learn more about the genetic information obtained from cancer exome sequencing, future clinical trials will allow for the inclusion of patients with specific genetic alterations, and therefore a better access to cancer drugs."

FUTURE ASSAYS ON PANCREATIC CANCER

Currently, one the main objectives for the team is to study the efficiency of the procedures in a larger number of patients with advanced pancreatic cancer, thereby comparing them to standard treatments.

Pancreatic cancer often has a poor prognosis, with survival rates of less than 1 year. It is a complex and heterogeneous disease, meaning that the personalised study of the most relevant mutations in tumour growth (driver mutations) could be a promising strategy in the search for new treatments.


'/>"/>

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert  

Related biology news :

1. Report presents designs for study of cancer risks near US nuclear facilities
2. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
3. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
4. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
5. Crop Science Society of America presents 2012 class of fellows
6. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
7. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
8. July meeting presents animal and dairy science
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
11. Yin-yang effect of sodium and chloride presents salt conundrum
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CNIO team presents a new strategy to personalise cancer therapies
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 22, 2016  According to Kalorama Information, the ... (NGS) market include significant efforts in automation as ... accessible and affordable sequencers, say the healthcare market ... consumables including sample prep materials.  The healthcare market ... Preparation for Next Generation Sequencing (NGS) , highlights ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate ... tissue — promise to enable both compact, wearable devices for point-of-care diagnostics as well ... the skin. , Recent work and visionary future directions are detailed in a new ...
Breaking Biology Technology: